Abstract
Virus infection and oncogenesis are two tightly linked processes. Some viruses are endowed with a direct transforming capability and infection activates inflammation that, in turn, favours tumor progression. Also, both inflammation and tumor trigger (and are strongly dependent from) angiogenesis. Finally, some oncogenic viruses release “virokines” that contribute to the development of virus-associated tumors. At a molecular level, viral proteins, cytokines, receptors and adhesion molecules “cross-contribute” to the different processes and, amazingly, many of them bind to heparin and to heparan sulfate proteoglycans to exert their functions. Heparin-like polysulfated (PS) or polysulfonated (PSN) compounds are an heterogeneous group of natural or synthetic molecules whose prototypes are PS heparin and PSN suramin. They vary in their backbone structure, length, number/disposition of sulfated/sulfonated groups. Different combinations of these features confer to PS/PSN the capacity to bind with variable specificity to those heparin-binding proteins that “cross-contribute” to virus infection and tumor progression. Taken together, these considerations suggest that heparin-like PS/PSN antagonists may act as multitarget drugs that may control at once virus infection and tumor progression by targeting different proteins simultaneously. Here we discuss the possibility to exploit PS/PSN compounds for the development of drugs at the cross-road of viral infection and oncogenesis, taking in consideration the past efforts, possible drawbacks and future perspectives.
Keywords: Heparan sulfate proteoglycans, oncogenic viruses, polysulfated, polysulfonated, infection, angiogenesis, inflammation, tumor, cancer, multitarget drugs, viruses
Current Pharmaceutical Design
Title: Polysulfated/Sulfonated Compounds for the Development of Drugs at the Crossroad of Viral Infection and Oncogenesis
Volume: 15 Issue: 25
Author(s): Marco Rusnati and Chiara Urbinati
Affiliation:
Keywords: Heparan sulfate proteoglycans, oncogenic viruses, polysulfated, polysulfonated, infection, angiogenesis, inflammation, tumor, cancer, multitarget drugs, viruses
Abstract: Virus infection and oncogenesis are two tightly linked processes. Some viruses are endowed with a direct transforming capability and infection activates inflammation that, in turn, favours tumor progression. Also, both inflammation and tumor trigger (and are strongly dependent from) angiogenesis. Finally, some oncogenic viruses release “virokines” that contribute to the development of virus-associated tumors. At a molecular level, viral proteins, cytokines, receptors and adhesion molecules “cross-contribute” to the different processes and, amazingly, many of them bind to heparin and to heparan sulfate proteoglycans to exert their functions. Heparin-like polysulfated (PS) or polysulfonated (PSN) compounds are an heterogeneous group of natural or synthetic molecules whose prototypes are PS heparin and PSN suramin. They vary in their backbone structure, length, number/disposition of sulfated/sulfonated groups. Different combinations of these features confer to PS/PSN the capacity to bind with variable specificity to those heparin-binding proteins that “cross-contribute” to virus infection and tumor progression. Taken together, these considerations suggest that heparin-like PS/PSN antagonists may act as multitarget drugs that may control at once virus infection and tumor progression by targeting different proteins simultaneously. Here we discuss the possibility to exploit PS/PSN compounds for the development of drugs at the cross-road of viral infection and oncogenesis, taking in consideration the past efforts, possible drawbacks and future perspectives.
Export Options
About this article
Cite this article as:
Rusnati Marco and Urbinati Chiara, Polysulfated/Sulfonated Compounds for the Development of Drugs at the Crossroad of Viral Infection and Oncogenesis, Current Pharmaceutical Design 2009; 15 (25) . https://dx.doi.org/10.2174/138161209789058156
DOI https://dx.doi.org/10.2174/138161209789058156 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review Exploring Therapeutic Worth of 1,3,4-Oxadiazole Tailored Compounds
Mini-Reviews in Medicinal Chemistry Impact of p53 arg72pro SNP on Breast Cancer Risk in North Indian Population
Current Genomics Endogenous Factors in the Recovery of Reproductive Function After Testicular Injury and Cancer
Current Molecular Medicine β-estradiol Induces Mitochondrial Apoptosis in Cervical Cancer through the Suppression of AKT/NF-κB Signaling Pathway
Recent Patents on Anti-Cancer Drug Discovery Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy
Current Cancer Drug Targets Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles
Current Gene Therapy Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Current Topics in Medicinal Chemistry The Impact of Tumor Physiology on Camptothecin-Based Drug Development
Current Medicinal Chemistry - Anti-Cancer Agents Fibroblast Growth Factor Receptor Signaling in Cancer Biology and Treatment
Current Signal Transduction Therapy Dual Topoisomerase I / II Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Design, Synthesis and Biological Evaluation of 4, 6-Coumarin Derivatives as Anti- Cancer and Apoptosis-Inducing Agents
Anti-Cancer Agents in Medicinal Chemistry Cisplatin Properties in a Nanobiotechnological Approach to Cancer: A Mini-Review
Current Cancer Drug Targets Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients Over a 4 Year Period
Current Drug Therapy Inflammation, Microenvironment, and the Immune System in Cancer Progression
Current Pharmaceutical Design Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View
Current Cancer Drug Targets Targeting the Folate Receptor: Effects of Conjugating Folic Acid to DOX Loaded Polymeric Micelles
Anti-Cancer Agents in Medicinal Chemistry Herpes Simplex Virus Vectors for the Nervous System
Current Gene Therapy Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Aryltetralin-type Lignan of Podophyllum: A Comprehensive Review
The Natural Products Journal <i>In Silico</i> Docking of Anti Cancerous Drugs with β-Cyclodextrin polymer as a Prominent Approach to Improve the Bioavailability
Anti-Cancer Agents in Medicinal Chemistry